S-1/A: NAYA Biosciences Files Amendment for $13 Million Unit Offering

NAYA Biosciences has filed an amendment to its registration statement for a unit offering of up to $13 million, including common stock or pre-funded warrants and common warrants.

Summary

• NAYA Biosciences is seeking to raise up to $13 million through a unit offering.
• Each unit will consist of one share of common stock or one pre-funded warrant, and one common warrant.
• The offering price is assumed to be $0.87 per unit.
• The company plans to use the proceeds to fund the second installment of the WFI purchase price, redeem Series C-2 preferred stock, pay outstanding debt, and for clinical trials, product development, marketing, and general corporate purposes.
• The company has engaged Maxim Group LLC as the exclusive placement agent for the offering.
• The offering is on a reasonable best efforts basis, with no minimum amount required to close.
• The company has a complex capital structure with multiple classes of preferred stock and convertible securities.
• The company has a history of net operating losses and needs additional capital to grow and finance its operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a promising pipeline and a diversified business model, it also faces significant financial and operational challenges. The need for additional capital and the history of net losses are concerning, leading to a lower sentiment score.

Positives

• The offering will provide NAYA Biosciences with additional capital to fund its operations and growth initiatives.
• The company has a diversified business model with both a fertility business and a therapeutics business.
• The company has a pipeline of clinical-stage therapeutics with potential for significant value creation.
• The company has a novel technology platform for developing multifunctional antibodies.
• The company has a commercial-stage fertility business with revenue-generating clinics and a medical device.

Negatives

• The company has a history of net operating losses and needs additional capital to grow and finance its operations.
• The company has a complex capital structure with multiple classes of preferred stock and convertible securities.
• The company is subject to significant competition in both the fertility and therapeutics markets.
• The company is subject to significant regulatory risks.
• The company is dependent on third-party manufacturers and suppliers.
• The company is subject to risks associated with doing business globally.
• The company is subject to risks in connection with changes in international, national, and local economic and market conditions.
• The company is susceptible to cybersecurity breaches and cyber-related fraud.
• The company may not be able to successfully integrate Legacy NAYA and achieve the benefits expected to result from the acquisition.
• The company may not be able to successfully manage Wisconsin Fertility Institute and to achieve the benefits expected to result from the acquisition.

Risks

• The company's financial situation creates doubt about its ability to continue as a going concern.
• The company may not be able to raise additional funding on acceptable terms, or at all.
• The company may not be able to successfully integrate Legacy NAYA and achieve the benefits expected to result from the acquisition.
• The company may not be able to successfully manage Wisconsin Fertility Institute and to achieve the benefits expected to result from the acquisition.
• The company's business has posted net operating losses, has a limited operating history, and needs additional capital to grow and finance its operations.
• The company is subject to risks associated with doing business globally.
• The company is subject to significant domestic and international governmental regulation.
• The company is subject to risks relating to federal and state healthcare fraud, waste, and abuse laws.
• The company may not be able to develop or continue its business if it fails to retain key personnel.
• Currency exchange rate fluctuations may affect the results of the company's operations.
• The company is subject to risks in connection with changes in international, national, and local economic and market conditions.
• Social media platforms present risks and challenges.
• The company is susceptible to cybersecurity breaches and cyber-related fraud.
• The company's existing INVO Centers were established as joint ventures with medical partners, and future INVO Centers may also be established as joint ventures.
• The company's fertility business is subject to significant competition.
• The company needs to manage growth in its fertility operations, and it may not be successful in implementing its growth strategy.
• The company may not be successful at managing clinics.
• The company faces potential liability as a provider of a medical device.
• If the company fails to maintain adequate quality standards for its products, its reputation and business may be adversely affected and harmed.
• The company heavily relies on third party package delivery services, and a significant disruption in these services or significant increases in prices may disrupt its ability to import or export materials, increase its costs and negatively affect its ability to achieve and maintain profitability.
• The company will need additional, qualified personnel in order to expand its fertility business.
• The FDA regulatory review process for medical devices is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent the company from commercializing its products.
• Improper marketing and promotion or off-label use of the company's product could lead to investigations and enforcement by governmental bodies including product recalls or market withdrawal, may harm its reputation and business, and could result in product liability suits.
• If the company fails to comply with the FDAs Quality System Regulation (QSR) or comparable EU requirements, the FDA or EU competent authorities could take various enforcement actions, including suspending its FDA clearance to market, withdrawal of its EU CE Certificate or halting its manufacturing operations, and its business would suffer.
• The company is subject to continuing regulation by the FDA, and failure to comply may materially harm its business.
• The company's products are generally subject to regulatory requirements in foreign countries in which it sells those products.
• If third-party payers do not provide adequate coverage and reimbursement for INVOcell and the IVC procedure, the company may be unable to generate significant revenue.
• The company may be subject to risks related to changes in laws regarding abortion, which can affect how a fertility clinic must treat and handle embryos.
• The company's ability to develop proprietary technology platforms and products and its future growth depend on retaining NAYA Therapeutics key personnel and recruiting additional qualified personnel.
• The regulatory processes that will govern the approval of the company's product candidates are complex and changes in regulatory requirements could result in delays or discontinuation of development or unexpected costs in obtaining regulatory approval.
• The company is dependent on the successful clinical development, regulatory approval and subsequent commercialization of its product candidates.
• The company's fully integrated product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or its inability to achieve regulatory approval, commercialization, or payor coverage of its product candidates.
• Even if any of the company's product candidates receive marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
• Even if the company obtains and maintains approval for its product candidates from the FDA, it may never obtain approval outside the United States, which would limit its market opportunities.
• The company expects the product candidates it develops will be regulated as biologics, and therefore they may be subject to competition sooner than anticipated.
• The company's product candidates are in early stages of development, and therefore will require extensive additional preclinical and clinical testing.
• The company's approach to the development of product candidates based on its FLEX-NK cell engager antibody platform is unproven, and it does not know whether it will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of its product candidates or render its platforms obsolete.
• If the company encounters difficulties in enrolling patients in its future clinical trials, its clinical development activities could be delayed or otherwise adversely affected.
• The company may not be able to file Investigational New Drug Applications to commence future clinical trials on the timelines it expects, and even if it is able to, the FDA or comparable foreign authority may not permit it to proceed.
• The company's product candidates may cause serious adverse events or undesirable side effects or have other properties that may delay or prevent regulatory approval, cause it to suspend or discontinue clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
• Interim, top-line and preliminary data from the company's clinical trials that it announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• The company faces significant competition from other biotechnology and pharmaceutical companies, which may result in others discovering, developing, or commercializing products before or more successfully than it does.
• NY-500 may not surpass the current standard of care or that sales of NY-500, if ever approved, will approach or surpass the market leader.
• The company intends to study its product candidates in patient populations with significant comorbidities, and these patients may also receive treatment with cytotoxic lymphodepletion agents and other immunotherapies, and/or other treatments that may result in deaths or serious adverse or unacceptable side effects and require it to abandon or limit its clinical development activities.
• The company may not identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• If product liability lawsuits are brought against the company, it may incur substantial liabilities and may be required to limit commercialization of its product candidates.
• The manufacturing of the company's product candidates will be very complex.
• The company is dependent on strategic partnerships and collaboration arrangements for the development of its FLEX-NK bispecific antibody platform, and if these arrangements are unsuccessful, this could result in delays and other obstacles in the development, manufacture or commercialization of any of its product candidates.
• The company relies upon third parties to conduct certain research and development activities and assist it with its preclinical trials and future clinical trials and commercial sale, if approved, of its product candidates.
• A disruption to the company's internal or third-party manufacturing operations, or its third-party suppliers or manufacturers inability to manufacture sufficient quantities of its antibody and cell product candidates at acceptable quality levels or costs, or at all, could materially and adversely affect its business.
• The company's product candidates rely on the availability of specialty raw materials, which may not be available to it on acceptable terms or at all.
• If conflicts arise between the company and its collaborators or strategic partners, these parties may act in a manner adverse to it and could limit its ability to implement its strategies.
• The company may seek to form collaborations in the future with respect to its product candidates, but may not be able to do so, which may cause it to alter its development and commercialization plans.
• The company's business involves the use of hazardous materials which requires that it, and its third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict or interrupt its business.
• The company has established a partnership with CytoLynx for the development and commercialization of its NY-303 bispecific antibody in greater China and there are substantial operational, financial, regulatory and political risks with this collaboration.
• The company's products incorporate intellectual property rights developed by it that may be difficult to protect or may be found to infringe on the rights of others.
• The company's ability to develop proprietary technology platforms and products and its future growth depend on retaining NAYA Therapeutics key personnel and recruiting additional qualified personnel.
• The company is dependent on the successful clinical development, regulatory approval and subsequent commercialization of its product candidates.
• The company's fully integrated product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or its inability to achieve regulatory approval, commercialization, or payor coverage of its product candidates.
• Even if any of the company's product candidates receive marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
• Even if the company obtains and maintains approval for its product candidates from the FDA, it may never obtain approval outside the United States, which would limit its market opportunities.
• The company expects the product candidates it develops will be regulated as biologics, and therefore they may be subject to competition sooner than anticipated.
• The company's product candidates are in early stages of development, and therefore will require extensive additional preclinical and clinical testing.
• The company's approach to the development of product candidates based on its FLEX-NK cell engager antibody platform is unproven, and it does not know whether it will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of its product candidates or render its platforms obsolete.
• If the company encounters difficulties in enrolling patients in its future clinical trials, its clinical development activities could be delayed or otherwise adversely affected.
• The company may not be able to file Investigational New Drug Applications to commence future clinical trials on the timelines it expects, and even if it is able to, the FDA or comparable foreign authority may not permit it to proceed.
• The company's product candidates may cause serious adverse events or undesirable side effects or have other properties that may delay or prevent regulatory approval, cause it to suspend or discontinue clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
• Interim, top-line and preliminary data from the company's clinical trials that it announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• The company faces significant competition from other biotechnology and pharmaceutical companies, which may result in others discovering, developing, or commercializing products before or more successfully than it does.
• NY-500 may not surpass the current standard of care or that sales of NY-500, if ever approved, will approach or surpass the market leader.
• The company intends to study its product candidates in patient populations with significant comorbidities, and these patients may also receive treatment with cytotoxic lymphodepletion agents and other immunotherapies, and/or other treatments that may result in deaths or serious adverse or unacceptable side effects and require it to abandon or limit its clinical development activities.
• The company may not identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• If product liability lawsuits are brought against the company, it may incur substantial liabilities and may be required to limit commercialization of its product candidates.
• The manufacturing of the company's product candidates will be very complex.
• The company is dependent on strategic partnerships and collaboration arrangements for the development of its FLEX-NK bispecific antibody platform, and if these arrangements are unsuccessful, this could result in delays and other obstacles in the development, manufacture or commercialization of any of its product candidates.
• The company relies upon third parties to conduct certain research and development activities and assist it with its preclinical trials and future clinical trials and commercial sale, if approved, of its product candidates.
• A disruption to the company's internal or third-party manufacturing operations, or its third-party suppliers or manufacturers inability to manufacture sufficient quantities of its antibody and cell product candidates at acceptable quality levels or costs, or at all, could materially and adversely affect its business.
• The company's product candidates rely on the availability of specialty raw materials, which may not be available to it on acceptable terms or at all.
• If conflicts arise between the company and its collaborators or strategic partners, these parties may act in a manner adverse to it and could limit its ability to implement its strategies.
• The company may seek to form collaborations in the future with respect to its product candidates, but may not be able to do so, which may cause it to alter its development and commercialization plans.
• The company's business involves the use of hazardous materials which requires that it, and its third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict or interrupt its business.
• The company has established a partnership with CytoLynx for the development and commercialization of its NY-303 bispecific antibody in greater China and there are substantial operational, financial, regulatory and political risks with this collaboration.
• The company's products incorporate intellectual property rights developed by it that may be difficult to protect or may be found to infringe on the rights of others.
• This is a reasonable best efforts offering, in which no minimum number or dollar amount of securities is required to be sold, and the company may not raise the amount of capital it believes is required for its business plans.
• Assuming that the company is able to sell the maximum number of shares of common stock in this offering, it expects that the consummation of this offering could cause the price of its Common Stock to decline.
• The company has issued a substantial number of securities convertible into shares of its common stock which could result in substantial dilution to the ownership interests of its existing stockholders.
• The company's secured debt instruments and preferred stock contain numerous restrictive covenants that limit managements discretion to operate its business.
• Upon consummation of this offering, the company will be obligated to make payments on certain of its outstanding indebtedness.
• The company's stockholders may not approve its proposed stockholder matters.
• The company will have broad discretion in the use of the net proceeds from this offering and may fail to apply these proceeds effectively.
• There is no public market for the warrants or pre-funded warrants to purchase shares of the company's common stock being offered in this offering.
• Holders of the company's warrants and pre-funded warrants will have no rights as a common stockholder until they acquire its common stock.
• The warrants are speculative in nature.
• You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.
• If the company is unable to maintain compliance with all applicable continued listing requirements and standards of Nasdaq, its common stock will be delisted from Nasdaq.
• The company's common stock is subject to risks arising from restrictions on reliance on Rule 144 by shell companies or former shell companies.
• The company's directors have the right to authorize the issuance of shares of its preferred stock and additional shares of its common stock.
• The indemnification rights provided to the company's directors, officers and employees may result in substantial expenditures by it and may discourage lawsuits against its directors, officers and employees.
• The company's shares of common stock are thinly traded, and the price may not reflect its value; there can be no assurance that there will be an active market for its shares now or in the future.
• The company does not expect to pay any dividends to shareholders.
• The company's revenue and operating results could fluctuate significantly from quarter to quarter, which may cause its stock price to decline.
• The company may have difficulty raising the necessary capital to fund operations and the required $7.5 million in additional payments for the Wisconsin Fertility acquisition because of the thin market and market price volatility for its shares of common stock.
• An active trading market for the company's common stock may not be sustained.
• The trading price of the company's common stock is highly volatile, which could result in substantial losses for purchasers of its common stock.
• Recent economic trends could adversely affect the company's financial performance.
• The company is a Smaller Reporting Company, or SRC, and the reduced disclosure requirements applicable to SRCs may make its common stock less attractive to investors.
• The company has broad discretion over the use of its cash and cash equivalents and may not use them effectively.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about the company's business, its share price and trading volume could decline.
• Stockholders may be diluted significantly through the company's efforts to obtain financing and from issuance of additional shares of its common stock, including such issuances of shares for services.
• The company is subject to the reporting requirements of U.S. federal securities laws, which can be expensive.
• If the company fails to comply with internal control attestation requirements could lead to loss of public confidence in its financial statements and negatively impact its stock price.

Future Outlook

The company intends to use the proceeds from the offering to fund clinical trials, product development, marketing, and general corporate purposes. The company also plans to acquire additional clinical stage assets and enter into revenue-generating development partnerships.

Management Comments

• The company believes its expanded corporate platform and strategy enhances its potential for value creation for shareholders through the combination of the existing revenue generating fertility business with the unique potential of innovative therapeutics.
• The company believes its hub and spoke model will enable efficient acquisition, development, and partnering of assets as well as optimized return on investment.

Industry Context

The document highlights the growing market for bispecific antibodies and the increasing demand for assisted reproductive technology. The company is positioning itself to capitalize on these trends with its novel technology platforms and commercial-stage fertility business.

Comparison to Industry Standards

• The company's hub and spoke model is similar to that of other biotechnology companies such as Roivant, BridgeBio, and Puretech.
• The company's development of FLEX-NK cell engager antibodies is a novel approach to immunotherapy, with potential advantages over traditional monoclonal antibodies.
• The company's INVOcell device offers a more natural and affordable alternative to traditional IVF, addressing the need for more accessible fertility treatments.
• The company's clinical development plan for NY-303 and NY-338 is similar to that of other biotechnology companies developing novel therapeutics.
• The company's focus on AI-optimized antibodies is in line with the growing trend of using artificial intelligence in drug discovery and development.

Management Changes

Related Party Transactions

• The company has issued promissory notes to related parties, including its Chief Executive Officer and an entity controlled by its Chief Financial Officer.
• The company has entered into a loan agreement with Cytovia Therapeutics, Inc., a related party.
• The company has entered into an asset purchase agreement with Cytovia Therapeutics Holdings, Inc. and Cytovia Therapeutics, LLC, related parties.

Stakeholder Impact

• Shareholders will be diluted by the issuance of new shares in the offering.
• Shareholders may experience a decline in the stock price due to the offering.
• Employees may benefit from the company's growth and development.
• Customers may benefit from the company's expanded access to fertility treatments and innovative therapeutics.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to initiate Phase I/IIa clinical trials for NY-303 and NY-338 in 2025.
• The company aims to advance NY-500 to a Phase I/IIa clinical trial in 2026.
• The company intends to acquire additional clinical stage assets.
• The company plans to enter into revenue-generating development partnerships with larger pharmaceutical/biotech companies.
• The company will seek stockholder approval for various matters, including an increase in authorized shares and a reverse stock split.

Key Dates

Keywords

biotechnology, pharmaceutical, oncology, autoimmune, fertility, bispecific antibodies, natural killer cells, clinical trials, medical devices, capital raise, FLEX-NK, GPC3, CD38, Hepatocellular carcinoma, Multiple myeloma, IVF, INVOcell